Analysts See $-0.57 EPS for Gemphire Therapeutics Inc. (GEMP)

July 14, 2018 - By Jason Dias

Analysts expect Gemphire Therapeutics Inc. (NASDAQ:GEMP) to report $-0.57 EPS on August, 13.They anticipate $0.17 EPS change or 22.97 % from last quarter’s $-0.74 EPS. After having $-0.58 EPS previously, Gemphire Therapeutics Inc.’s analysts see -1.72 % EPS growth. The stock increased 1.78% or $0.14 during the last trading session, reaching $8.01. About 329,086 shares traded. Gemphire Therapeutics Inc. (NASDAQ:GEMP) has declined 37.19% since July 14, 2017 and is downtrending. It has underperformed by 49.76% the S&P500.

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease and nonalcoholic fatty liver disease/non-alcoholic steatohepatitis . The company has market cap of $114.00 million. It is developing gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy and for those patients who present with NASH. It currently has negative earnings.

More notable recent Gemphire Therapeutics Inc. (NASDAQ:GEMP) news were published by: which released: “Mid-Day Market Update: Crude Oil Up Over 1%; Gemphire Therapeutics Shares Spike Higher” on June 29, 2018, also with their article: “After-Hours Stock Movers 06/28: (GEMP) (NKE) (VRTX) Higher; (SNX) (CVG) Lower (more…)” published on June 28, 2018, published: “Benzinga Pro’s 5 Stocks To Watch Today” on June 29, 2018. More interesting news about Gemphire Therapeutics Inc. (NASDAQ:GEMP) were released by: and their article: “Gemphire: Is There More To This Strong Grower?” published on July 13, 2018 as well as‘s news article titled: “Jefferies sees more headroom for Gemphire, up 97%” with publication date: June 29, 2018.

Gemphire Therapeutics Inc. (NASDAQ:GEMP) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.